SUMANTA DAS

Dr. SUMANTA DAS

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 May 2024 in Pathology - Research and Practice
Verified
Journal Article
Closed access
SDSUMANTA DAS
SUMANTA DAS
SASunita Ahlawat
Sunita Ahlawat
APArun Kumar Panda
Arun Kumar Panda
JSJayati Sarangi
Jayati Sarangi
PJPriti Jain
Priti Jain
RPRana Patir
Rana Patir

4 October 2024 in Pathology - Research and Practice
Verified
Journal Article
Closed access
AKAdil Aziz Khan
Adil Aziz Khan
NRNaveen Kumar R
Naveen Kumar R
SCSushanta Chakma
Sushanta Chakma
SDSUMANTA DAS
SUMANTA DAS

1 June 2025 in Neuropathology
Verified
Journal Article
Closed access
SDSUMANTA DAS
SUMANTA DAS
BCBheru Dan Charan
Bheru Dan Charan
SNShrinidhi Nathany
Shrinidhi Nathany
RGRakesh Kumar Gupta
Rakesh Kumar Gupta
MSMehar Chand Sharma
Mehar Chand Sharma
SASunita Ahlawat
Sunita Ahlawat

1 January 2024 in Clinical Neuropathology
Verified
Journal Article
Closed access
SDSUMANTA DAS
SUMANTA DAS
SASunita Ahlawat
Sunita Ahlawat
JSJayati Sarangi
Jayati Sarangi
APArun Kumar Panda
Arun Kumar Panda
PJPriti Jain
Priti Jain
RPRana Patir
Rana Patir
Thyroid transcription factor-1 (TTF-1) is a nuclear protein primarily recognized for its role in the development and differentiation of thyroid, lung, and certain diencephalic tissues. Although well-established as an immunohistochemical marker in thyroid and lung cancers, recent studies have explored its expression and diagnostic value in primary central nervous system (CNS) tumors. This systematic review aims to consolidate current knowledge on TTF-1 immunohistochemistry in primary CNS tumors, assessing its prevalence, diagnostic utility, and clinical implications. The review encompasses various CNS tumor types, including subependymal giant cell astrocytoma, chordoid glioma, pituicytoma, ependymomas, astrocytomas, glioblastomas, medulloblastomas, and choroid plexus tumors, highlighting the potential role of TTF-1 in differentiating these neoplasms from other CNS and metastatic tumors. By synthesizing findings from multiple studies, this review underscores the diagnostic value of TTF-1 in the neuropathological evaluation of CNS tumors and suggests directions for future research to refine its clinical application.

1 October 2025 in Pathologica
Verified
Journal Article
Open access
SDSUMANTA DAS
SUMANTA DAS
PMPallavi Mishra
Pallavi Mishra
SASunita Ahlawat
Sunita Ahlawat
SMARCA4-deficient tumors of the thoracic cavity represent a newly emerging group of aggressive neoplasms driven by inactivation of the SMARCA4 gene, a key member of the SWI/SNF chromatin remodeling complex. These tumors are broadly classified into thoracic SMARCA4-deficient undifferentiated tumors (SMARCA4-UT) and SMARCA4-deficient non-small cell lung carcinomas (SMARCA4-dNSCLC). Despite some overlap in genomic alterations, especially smoking-related mutations like TP53, KRAS, and KEAP1, these entities differ in histomorphology, immunoprofile, and biological behavior. SMARCA4-UTs are undifferentiated, often rhabdoid in appearance, with loss of epithelial markers and gain of stem cell markers such as SOX2 and SALL4, while SMARCA4-dNSCLCs retain some epithelial differentiation. Radiologically, these tumors often present as large central thoracic masses with high metabolic activity and early metastases. Both tumor types show poor prognosis, with limited response to conventional therapies. Immunotherapy, particularly immune checkpoint inhibitors, shows promise even in PD-L1-negative cases, and emerging epigenetic and molecular targeted therapies are under investigation. It is crucial to distinguish SMARCA4-UT and SMARCA4-dNSCLC by appropriate use of histopathology, immunohistochemistry, and molecular studies, considering the prognosis and treatment response. Our review focuses on the advancement of understanding the clinicopathological spectrum of both entities, their genetic landscape, and current treatment options.

19 December 2024 in International Journal of Surgical Pathology
Verified
Journal Article
Closed access
SDSUMANTA DAS
SUMANTA DAS
SASunita Ahlawat
Sunita Ahlawat
JSJayati Sarangi
Jayati Sarangi
RGRakesh Kumar Gupta
Rakesh Kumar Gupta
PJPriti Jain
Priti Jain
RPRana Patir
Rana Patir
Isocitrate dehydrogenase (IDH) mutant gliomas are classified as astrocytoma or oligodendroglioma based on the recent application of ATRX mutation, TP53 mutation, and 1p/19q co-deletion. Astrocytomas classically show ATRX and TP53 mutations, whereas oligodendrogliomas are defined by 1p/19q co-deletion. However, there are reports of gliomas that harbor both astrocytoma and oligodendroglioma morphologically and molecularly. Here we present a patient of a 29-year-old woman who presented with a headache and underwent gross total excision. Magnetic resonance imaging showed a right frontal space-occupying lesion with T2 fluid-attenuated inversion recovery mismatch. Histology showed 2 distinct areas of morphology compatible with oligodendroglioma and astrocytoma. Immunohistochemistry showed both components being positive for IDH R132H. Alpha thalassemia/mental retardation syndrome X-linked (ATRX) showed loss of nuclear expression and p53 was strongly positive in the morphologic astrocytoma component, whereas ATRX was retained and p53 was negative in the morphologic oligodendroglioma component. Fluorescence in situ hybridization showed 1p/19q co-deletion in the oligodendroglioma component while co-deletion was absent in the astrocytoma component. TERT mutation was present in the oligodendroglioma component, whereas it was absent in the astrocytoma component. Although rare, gliomas harboring both oligodendroglioma and astrocytoma components in a single tumor exist and show genetically distinct areas.